Weitzel, ThomasPérez, CariciaTapia, DanixaLegarraga, PaulettePorte, Lorena2022-03-282022-03-282021Weitzel T, Pérez C, Tapia D, Legarraga P, Porte L. SARS-CoV-2 rapid antigen detection tests. Lancet Infect Dis. 2021 Aug;21(8):1067-1068. doi: 10.1016/S1473-3099(21)00249-8. Epub 2021 May 4. PMID: 33961799; PMCID: PMC8096320.https://doi.org/10.1016/S1473-3099(21)00249-8http://hdl.handle.net/11447/5834Papers who discuss the benefits and limitations of SARS-CoV-2 antigen rapid detection tests (AgRDTs) for scaling up diagnostic capacities in different settings. As recent evaluations suggest, Ag-RDTs can reliably detect patients during the initial infective phase of COVID-19 (when patients have high viral loads). As the authors emphasise, the screening of asymptomatic individuals in low-prevalence settings is hampered by imperfect specificity. The dilemma that most detected cases represent false positives rather than true infections might require a twotier approach with molecular confirmation, affecting the practicality and acceptance of such a strategy. Here we suggest alternative strategies to optimise the use of AgRDTs in asymptomatic populations with low positivity likelihood.enAntigens, ViralCOVID-19 TestingCOVID-19SARS-CoV-2Article